Strategies to Estimate And Improve Drug Tolerance in Anti-Drug Antibody Assays
Authors:
- 1 August 2012
- journal article
- research article
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (16) , 1999-2012
Abstract
Drug tolerance of anti-drug antibody (ADA) assays is becoming increasingly important due to the high number of newly emerging long-acting drugs. Methods to estimate and improve drug tolerance in ADA assays are needed. The relevance and precision of drug tolerance estimates in a bridging ELISA depended on characteristics and concentration of the surrogate control antibody together with assay cut point level. Stepwise and coincubation procedures were optimized for drug tolerance and sensitivity by adapting concentrations of reagents used for capture and detection of ADAs. In combination with acid treatment of samples, increase in drug tolerance of over 20-fold was achieved without losing sensitivity in two different assays. Acid treatment reduced drug interference observed in preclinical samples and prevented underestimation of ADA response. In a risk-based approach it may be possible to reliably predict in vivo drug tolerance using carefully chosen surrogate controls. General guidelines for development of drug-tolerant bridging ELISAs are presented.Keywords
This publication has 14 references indexed in Scilit:
- Electrochemiluminescence in BioanalysisBioanalysis, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsJournal of Immunological Methods, 2008
- A broad range of Fab stabilities within a host of therapeutic IgGsBiochemical and Biophysical Research Communications, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigenJournal of Immunological Methods, 2005
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Direct measurement of antibody affinity distribution by Haften-inhibition enzyme immunoassayMolecular Immunology, 1984